Welcome to the twenty-seventh edition of The Weekly Briefing!
Each week, we break down the biggest commercial stories shaping businesses, from major deals to regulatory changes, and explain why they matter.
Our goal is simple: help you build commercial awareness while understanding the legal issues behind the headlines.
Why are companies like BMW cutting thousands of jobs?
BMW’s decision to cut around 8,000 jobs highlights the pressure facing some of the world’s biggest car manufacturers as the electric vehicle market becomes increasingly competitive.
One of the biggest challenges comes from Chinese EV manufacturers such as BYD. These companies have been able to produce technology-focused electric vehicles at prices that many European manufacturers have struggled to match. With features such as advanced infotainment (a blend of information and entertainment) systems, competitive pricing and growing consumer appeal, Chinese brands are forcing established manufacturers to rethink how they compete.
BMW’s partnership with Qualcomm demonstrates this shift. The deal will see Qualcomm supply chips for BMW’s future vehicle platforms, supporting areas such as digital cockpits and advanced driver-assistance systems. The agreement highlights how competition in the automotive sector is no longer only about engines and design, but increasingly about software, artificial intelligence and the technology inside the vehicle.
What makes this challenge more significant is that Chinese EV makers remain highly competitive despite the EU introducing tariffs on imports. While these measures aim to address concerns around competition from Chinese manufacturers, companies such as BYD continue to put pressure on brands like BMW, Mercedes-Benz and Volkswagen.
For law firms, the impact extends far beyond BMW. If European manufacturers continue to face pressure from Chinese competitors, many will be forced to rethink their long-term strategy. That could mean restructurings, investments in new battery and EV technology, joint ventures, acquisitions or supply chain changes as manufacturers look to reduce costs without compromising the quality their brands are known for. Each of those decisions creates legal work across corporate, employment, commercial and regulatory teams.
Why are pharmaceutical companies spending billions on acquisitions?
Healthcare has become one of the busiest industries for mergers and acquisitions, with pharmaceutical companies constantly looking for ways to expand their drug pipelines and secure the next breakthrough treatment.
AstraZeneca’s potential acquisition of Bristol Myers Squibb illustrates this wider trend. Rather than spending years developing every new treatment internally, pharmaceutical companies are increasingly using acquisitions to gain access to promising research, specialist teams and existing medicines.
This is particularly important in areas such as cancer treatment, where companies are racing to develop new therapies. Creating a successful drug can take years of research and billions of pounds of investment, meaning acquiring another company can be a faster way to strengthen their position.
For law firms, the growth of pharmaceutical M&A creates opportunities for teams with strong life sciences and corporate practices. However, these deals also raise competition concerns. While acquisitions can help companies bring new treatments to patients quicker, regulators must consider whether continued consolidation could leave too much control of important medicines in the hands of a small number of businesses.